Novo Nordisk insulin analogues have proven safety profiles
28 June 2009
On Friday 26 June, Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) published online data from four studies relating to a possible link between a long-acting insulin analogue, insulin glargine, and cancer. As a basis for such a possible link, an accompanying editorial explains that certain insulin analogues have a structure making them more likely to bind to the IGF-1 receptor which is known to be involved in promoting tumour growth.
To avoid unnnecessary speculation about whether Novo Nordisk insulin analogues may be associated with an increased risk of cancer, the company has issued a company announcement.
RSS Feed
The latest Novo Nordisk news are now available through Really Simple Syndication - RSS.
